TCES for Upper Limb Function in Cervical SCI

Spinal cord injury (SCI) can be defined as a loss of communication between the brain and the body due to damage to pathways within the spinal cord. Injury to the cervical levels of the spinal cord are more common than injury to the lower segments of the spinal cord, thus tetraplegia is more common than paraplegia (Thompson et al., 2014). Tetraplegics rank regaining arm and hand function as their main priority for rehabilitation, five times greater than bowel, bladder, sexual or lower extremity function (Anderson, 2004). However, compared to recent advances made in recovery of ambulatory function, research that strives to uncover how best to optimise arm/hand rehabilitation after SCI is very limited. Thus identifying and optimising efficacious therapies to restore functional arm and hand recovery is an important clinical, economic and social goal.

While promising molecular strategies have emerged to reduce secondary injury and promote axonal regrowth, an effective cure eludes people with cervical SCI, and overall recovery of arm and hand function using these means remains limited (Levi et al., 2018). Functional training, or task specific training of a motor function (e.g. reaching and grasping), is currently the most effective evidence-based way of enhancing plasticity to recover motor function. A promising approach is the use of stimulation-based rehabilitative therapies promoting neural plasticity along the spinal cord/corticospinal tract. Among these, transcutaneous electrical stimulation (TCES) (Gerasimenko et al., 2015) was demonstrated to be effective for improving hand grip strength in people with spinal cord injury (Gad et al., 2018). The investigators hypothesise that combining upper limb practice (ULTP) and TCES to the cervical spinal cord over the course of 4 weeks, could affect arm/ hand function and quality of life to a greater extent than ULTP by itself.

The principal aim of the study is to test the effects of transcutaneous electrical stimulation on arm and hand functions in individuals with cervical spinal cord injury. In addition, the investigators aim to assess the neurophysiological mechanisms with which transcutaneous electrical stimulation supports the observed changes in hand/arm function.

The primary objective of the study is to measure and compare the changes in hand and arm functions, assessed through the Graded and Redefined Assessment of Strength, Sensibility and Prehension test (GRASSP) tool, occurring over the course of the two interventions (ULTP and ULTP + TCES). In addition, secondary objectives are:

To explain the neurophysiological mechanisms with which transcutaneous electrical stimulation results in changes in hand/arm function.

To establish a clearly defined, reproducible protocol for establishing participant specific TCES settings.

To understand factors that contribute to participants wanting to use TCES and their experience of using TCES.

The study will consist of two weeks of baseline measurements, 8 weeks of intervention (4 weeks of ULTP and 4 weeks of TCES + ULTP) in a cross-over design, followed by two-weekly and a 3 month follow-up with no further intervention (Inanici et al., 2018). The baseline measurements (see primary and secondary outcome measures) are necessary to document stability of functional status. Baseline measures will take place over 2 sessions, each week (e.g. 4 baseline testing sessions).

Participation to the study will span over the course of 25 weeks. On the first 2 weeks, participants will attend the lab twice per week. On the following 8 weeks, participants will attend the lab three times per week. On week 11, participants will attend the lab twice. On week 12, participants and their carers will be invited to a semi-structured interview. There will then be a 3-months break during which the participants are not required to attend the lab, after which (week 25) they will take part on two follow-up sessions.

Inclusion criteria

Cervical (between C3 and C7) spinal cord injury at least 1 year prior to the study.

• Between 18 and 80 years of age.
• Difficulty with hand functions in activities of daily living (e.g. dressing, grooming, feeding)
• Stable medical condition without cardiopulmonary disease or frequent autonomic dysreflexia that would contraindicate participation in upper extremity rehabilitation or testing activities.
• Capable of performing simple cued motor tasks such as reaching and touching or grasping objects.
• Ability to attend 3 sessions of weekly experimental sessions and testing activities over the course of 8 weeks.
• Ability to provide informed consent (either verbally or in writing).
• Ability to read/speak English.

Exclusion criteria

• History of additional neurologic disease, such as stroke, multiple sclerosis, traumatic brain injury, etc.
• Peripheral neuropathy (diabetic polyneuropathy, entrapment neuropathy, etc.).
• Rheumatic diseases (rheumatoid arthritis, systemic lupus erythematosus, etc.).
• Active cancer
• Cardiovascular or pulmonary disease that would prevent full participation in the upper limb practice intervention
• Ongoing medical complications (such as unhealed fracture, contracture, pressure sore, or urinary tract infection or other illnesses) that might interfere with upper extremity rehabilitation or testing activities
• Any condition that would render the patient unable to safely cooperate with the study tests as judged by the screening physician
• Personal or familial history of epilepsy
• Pregnancy
• Botulinum toxin injections in the prior 6 months
• Dependent on ventilation support
• Implanted stimulator (e.g. vagus nerve stimulator, pacemaker, cochlear implant, etc) 0r infusion device (e.g. insulin pump, etc).
• Cardiac pacemaker or intracardial lines. Exclusions for general safety
• Pregnancy
• Alcohol and/or drug abuse.
• Unable to read and/or comprehend the consent form.
• Unable to understand the instructions given as part of the study.